GSK and UK researchers plan to study Shingrix and dementia risk reduction link
GSK is collaborating with the UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to investigate …
Post
-
-
Novo Nordisk earmarks $2bn for Chinese “triple G” weight loss shot
Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug in a deal worth …
-
Alumis and Kaken sign agreement in Japan to develop ESK-001
Alumis and Kaken Pharmaceutical have entered a partnership and licensing agreement for the development, manufacture and commercialisation of the former’s …
-
WuXi AppTec sells UK-US units, but annual results show foreign contracts continue despite China tensions
WuXi AppTec (Shanghai, China) has sold off two US/UK businesses in February and March, it revealed in its annual results …
-
Overcoming regulatory challenges in sterile manufacturing
In parenteral sterile fill-finish manufacturing, drug products must be free from viable microorganisms – critical for products administered via injection …
-
UKHSA unveils high-risk pathogen list to drive innovation
The UK Health and Security Agency (UKHSA) has released a new watch list of 24 infectious diseases that could pose …
-
Trump tariffs drive pharma manufacturing to US but risk inflation and disruption
The pharma industry has been left reeling by the recent news of US government trade tariffs, with companies Eli Lilly …
-
EMA to review GSK’s Nucala for COPD treatment expansion
The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on maintenance for …
-
Sermonix and Regor to enhance breast cancer treatment options
Sermonix Pharmaceuticals and Regor Therapeutics have announced a strategic partnership to discover and develop therapeutics in the breast oncology area. The …
-
Tempero secures $70m to advance addiction treatment candidate
Tempero Bio has raised $70m in Series B financing to advance its lead candidate TMP-301 through two clinical trials for …
-
Valneva outlays 40,000 vaccines to Réunion amidst chikungunya surge
Valneva will provide 40,000 doses of its chikungunya vaccine Ixchiq to French overseas territory La Réunion as part of efforts …
-
Alberta partners Siemens and the Alberta Cancer Foundation
The government of Alberta, Canada, has announced a collaboration with Siemens Healthineers and the Alberta Cancer Foundation, investing C$800m ($560m) …
-
Rising Sirturo resistance highlights urgent need for new TB therapies
There have been widespread reports that more effort and funding is needed to combat the TB crisis. As more cases …
-
Augustine secures $85m to advance Charcot-Marie-Tooth candidate
Belgium-based biotech Augustine Therapeutics has raised €78m ($85m) in funding to support the development of its lead candidate as it …
-
FDA approves IND application for Everest’s cancer vaccine
The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application for Everest Medicines’ tumour-associated antigen …
